ArticleLeukemia research and treatment2013

Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy.

Chiara Sarlo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.